Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) have received an average rating of “Hold” from the seventeen research firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $49.90.

IONS has been the subject of several analyst reports. Goldman Sachs Group restated a “sell” rating and set a $30.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price target for the company in a report on Friday, October 27th. Needham & Company LLC restated a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Sunday, September 17th. Stifel Nicolaus restated a “hold” rating and set a $50.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, October 13th. Finally, BidaskClub upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 7th.

In other news, Chairman Stanley T. Crooke sold 22,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $50.01, for a total value of $1,100,220.00. Following the completion of the sale, the chairman now owns 58,014 shares in the company, valued at approximately $2,901,280.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Patrick R. O’neil sold 1,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $58.35, for a total transaction of $58,350.00. Following the completion of the sale, the senior vice president now owns 11,433 shares of the company’s stock, valued at approximately $667,115.55. The disclosure for this sale can be found here. Insiders sold a total of 102,781 shares of company stock valued at $5,733,330 in the last quarter. 2.13% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. grew its position in Ionis Pharmaceuticals by 17.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 367,550 shares of the company’s stock valued at $18,698,000 after purchasing an additional 54,587 shares during the period. Legal & General Group Plc grew its position in Ionis Pharmaceuticals by 9.7% in the 2nd quarter. Legal & General Group Plc now owns 44,480 shares of the company’s stock valued at $2,262,000 after purchasing an additional 3,944 shares during the period. Prudential Financial Inc. grew its position in Ionis Pharmaceuticals by 4.9% in the 2nd quarter. Prudential Financial Inc. now owns 8,641 shares of the company’s stock valued at $440,000 after purchasing an additional 400 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new stake in Ionis Pharmaceuticals in the 2nd quarter valued at $222,000. Finally, Principal Financial Group Inc. grew its position in Ionis Pharmaceuticals by 5.0% in the 2nd quarter. Principal Financial Group Inc. now owns 21,445 shares of the company’s stock valued at $1,091,000 after purchasing an additional 1,012 shares during the period. Institutional investors own 91.40% of the company’s stock.

Ionis Pharmaceuticals (NASDAQ IONS) traded up $0.05 during trading on Monday, reaching $53.22. 946,500 shares of the company’s stock traded hands, compared to its average volume of 1,066,889. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals has a 52-week low of $37.26 and a 52-week high of $65.51. The company has a market cap of $6,620.00, a price-to-earnings ratio of 380.14 and a beta of 2.86.

TRADEMARK VIOLATION WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/15/ionis-pharmaceuticals-inc-ions-receives-consensus-recommendation-of-hold-from-analysts.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.